Evidence map›Paper›PMID 40616628›Full record

ArticleAnnals of hematology2025

Safety of low-dose radiotherapy in newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a single-center retrospective analysis.

Shifeng Hao, Yukai Duan, Renjie Hua, Yuxiao Chang, Shuchang Li, Maosong Liu, Wanyue Zhao, Xiang Gao, Wenjie Gu, Qingjiang Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shifeng Hao *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Yukai Duan *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Renjie HuaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Yuxiao ChangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Shuchang LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Maosong LiuDepartment of Oncology, The Third Affiliated Hospital of XinXiang Medical University, Xinxiang, Henan Province, China.
Wanyue ZhaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Xiang GaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Wenjie GuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Qingjiang ChenDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. qingjiang_c@126.com.
Xudong ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. fcczhangxd@zzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the feasibility and safety of low-dose radiotherapy (RT) (< 50 Gy) in patients with stage I/II Extranodal NK/T-cell lymphoma (ENKTCL). Clinical and treatment data from 158 stage I/II ENKTCL patients who received combined chemoradiotherapy at the First Affiliated Hospital of Zhengzhou University from 2020 to 2022 were retrospectively analyzed to compare locoregional control (LC) and survival outcomes between high-dose (≥ 50 Gy) and low-dose (< 50 Gy) RT groups. All patients achieved an objective response (OR) after treatment, with a median follow-up of 51 months. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 90.1% and 81.7% in the high-dose group (n = 130), compared to 84.0% and 68.2% in the low-dose group (n = 28), with no significant statistical differences between the two groups. Notably, no local recurrence was observed in the low-dose group (100% local control rate), and the incidence of grade ≥ 3 RT-related adverse events (AEs) was significantly lower in the low-dose group than in the high-dose group. Preliminary evidence suggests that for newly diagnosed stage I/II ENKTCL patients receiving combined chemoradiotherapy, low-dose radiotherapy may not compromise LC and survival outcomes while reducing the incidence of grade 3-4 adverse events, with 40-45 Gy appearing to be the optimal dose range within the examined parameters.

Indexed as

Lymphoma, Extranodal NK-T-CellAdolescentAdultAgedAged, 80 and overChemoradiotherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingRadiotherapy DosageRetrospective StudiesSurvival RateYoung AdultAdverse eventsAsparaginaseExtranodal NK/T-cell lymphomaLow-dose radiotherapy

Identifiers

PMID40616628
PMCPMC12334506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.